{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:17:24Z","timestamp":1788023844735,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073439"],"award-info":[{"award-number":["82073439"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373475"],"award-info":[{"award-number":["82373475"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.intimp.2024.111716","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T07:38:00Z","timestamp":1709019480000},"page":"111716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis"],"prefix":"10.1016","volume":"130","author":[{"given":"RuiYuan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZiYue","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DanDan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9936-7607","authenticated-orcid":false,"given":"YuFei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChaoJing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-4854","authenticated-orcid":false,"given":"YaMei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-1051","authenticated-orcid":false,"given":"ZhiQiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2024.111716_b0005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5114\/ada.2019.89508","article-title":"How frequently does palmoplantar psoriasis affect the palms and\/or soles? A systematic review and meta-analysis","volume":"36","author":"Timotijevi\u0107","year":"2019","journal-title":"Postepy Dermatol. Alergol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111716_b0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/1346-8138.15826","article-title":"Similarity and difference between palmoplantar pustulosis and pustular psoriasis","volume":"48","author":"Yamamoto","year":"2021","journal-title":"J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.111716_b0015","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2014.04.063","article-title":"Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis","volume":"71","author":"Chung","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.111716_b0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13555-017-0207-0","article-title":"The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review","volume":"7","author":"Sanchez","year":"2017","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"1","key":"10.1016\/j.intimp.2024.111716_b0025","article-title":"Interventions for chronic palmoplantar pustulosis","volume":"1","author":"Obeid","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2024.111716_b0030","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.111716_b0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","article-title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway","volume":"85","author":"Bissonnette","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.111716_b0040","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production","volume":"136","author":"Mahil","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.111716_b0045","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jid.2016.04.038","article-title":"IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases","volume":"136","author":"Tauber","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2024.111716_b0050","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/jid.2013.44","article-title":"Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis","volume":"133","author":"Navarini","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2024.111716_b0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CCID.S67534","article-title":"Targeting of interleukin-17 in the treatment of psoriasis","volume":"7","author":"L\u00f8nnberg","year":"2014","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"10273","key":"10.1016\/j.intimp.2024.111716_b0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.111716_b0065","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/CCID.S407812","article-title":"Use of biological therapies for the management of pustular psoriasis: a new era?","volume":"16","author":"Megna","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"9993","key":"10.1016\/j.intimp.2024.111716_b0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2024.111716_b0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.111716_b0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.111716_b0085","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.111716_b0090","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"J. Eur. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.111716_b0095","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jdv.12343","article-title":"Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and\/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study","volume":"28","author":"Sigurgeirsson","year":"2014","journal-title":"J. Eur. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.111716_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109694","article-title":"Local injection of micro-dose anti-interleukin-17A antibody for palmoplantar pustulosis: a real-world study","volume":"253","author":"Xia","year":"2023","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.111716_b0105","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13006","article-title":"Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study","volume":"32","author":"Rompoti","year":"2019","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2024.111716_b0110","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14712598.2022.2029841","article-title":"Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.111716_b0115","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2022.05.047","article-title":"Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting","volume":"87","author":"Reolid","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111716_b0120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111716_b0125","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2024.111716_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.intimp.2024.111716_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.04.043","article-title":"Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis of randomized clinical trials","author":"Spencer","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.111716_b0140","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/1744666X.2023.2272049","article-title":"Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis","volume":"19","author":"Tsiogkas","year":"2023","journal-title":"Expert Rev. Clin. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924002340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:11:41Z","timestamp":1761588701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924002340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"alternative-id":["S1567576924002340"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111716","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111716"}}